Paget's bone disease treated with diphosphonate and calcitonin.
Patients with biochemically active Paget's disease were treated with a combination of disodium ethane-1-hydroxy-1, 1-diphosphonate (E.H.D.P.) and synthetic human calcitonin in low doses. The effect on biochemistry was greater and more consistent than that of even higher doses of human calcitonin. Bone biopsy showed decrease or even disappearance of abnormal osteoblasts and osteoclasts from pagetic lesions, and the addition of calcitonin to E.H.D.P. prevented the development of mineralisation defects.
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000473:pathology; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D009943:Organophosphorus Compounds; D002116:Calcitonin; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D006909:Hydroxyproline